| Abstract: | The author reviews the origins of the public policy debate concerning recombinant DNA technology and Congressional consideration of legislation to regulate recombinant DNA research. He notes especially his successful attempts to urge delay in passing legislation until there was complete evaluation of data — studies that ultimately resulted in noting that potential hazards were not as great as originally conceived. The author comments that strict regulation of recombinant DNA research, as proposed by some legislators, would have inhibited many of the great benefits that society is now receiving from this research. The author then raises a number of questions concerning government regulation and funding priorities on scientific and technological innovation, as well as government practices regarding basic and applied research in industrial and academic laboratories. A major concern of his is the government's ability to assess and manage risk. The author reviews one legislative proposal, which would have established risk analysis demonstration projects, and outlines a number of legislative initiatives that could impact the biotechnology industry and university-based research. He concludes by discussing opportunities for industrial applications of this technology and possible roles for Congress. |
